Live news related to GENFIT stock (FR0004163111): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on GENFIT mainly cover earnings publications, M&A activity et analyst notes. The stock trades at €11,76 on Euronext Paris, down 5,77% at the last update. This page lists the articles published on GENFIT stock to track the share price, company announcements and any item likely to influence market perception.
After acquiring nangibotide during summer 2026, Genfit plans to evaluate this drug candidate in acute-on-chronic liver failure (ACLF).The Lille-based …
The Scientific Index Council of Euronext Paris has decided to admit the Lille-based biopharmaceutical company to two of its indices following the annu…
The biopharmaceutical company based in Loos will participate in an American investor meeting dedicated to life sciences stocks. An opportunity for its…
The biopharmaceutical company Genfit will organize a virtual event bringing together a key opinion leader to present its non-invasive diagnostic platf…
Genfit announced on July 2nd the acquisition of Medicare coverage for NASHnext, its non-invasive diagnostic test for metabolic steatohepatitis (MASH).…
GENFIT announced positive Phase 1b data for GNS561 in combination with a MEK inhibitor in patients with KRAS-mutated cholangiocarcinoma, previously tr…
Genfit announced on Monday the launch of NASHnext, a non-invasive diagnostic service based on its NIS4 technology, through Labcorp's OnDemand platform…
Genfit announced on Monday the availability of its NASHnext diagnostic test on the digital platform Labcorp OnDemand, allowing patients to access scre…
Genfit announced on Monday a strong scientific presence at the EASL 2026 congress, with seven accepted posters covering its main assets in acute decom…
Genfit generated €9.6 million in revenue during the first three months of 2026 from royalties on Ipsen's sales of Iqirvo. This outcome arrived earlier…
